IL17A and psoriasis: Furthermore, combined administration of anti-IL-17A monoclonal antibody (secukinumab and ixekizumab) reduced fasting glucose levels in imiquimod treated mice and improved hyperglycemia in patients with psoriasis (33), suggesting that IL-17 may be a key cytokine linking psoriasis and hyperglycemia (34).